MONDAY, SEPTEMBER 26, 2016

Kineta to present new anti-viral, vaccine research at international conferences

Kineta, Inc., a biotechnology company that develops immune modulating treatments specifically for critical illnesses, will present data from its new anti-viral research and its vaccine adjuvant program at two international conferences held in Washington DC this spring.

The company will share information about its recent anti-viral research at the seventh International Symposium on Filoviruses from March 25-28. The research centers on the company's unique small molecule program, which creates an immune response that offers potent broad spectrum antiviral activity.

From April 7-9, company representatives also will attend the 15th annual World Vaccine Congress to present information about its vaccine adjuvant program. The vaccine adjuvant with broad immune-enhancing activity is being developed to provide antigen sparing and heterologous protection against various strains of the flu.

The Seattle-based company is privately held.  The company’ researchers are creating entirely novel classes of drugs using the latest in scientific research in order to change lives, and treat illness more effectively and safely.

Kineta's goal is to improve the quality of life for millions of people, whether they suffer with viral diseases, severe pain or autoimmune illnesses.